#### Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

#### INFINITY PHARMACEUTICALS, INC.

Form 3

February 07, 2014

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0104

0.5

Washington, D.C. 2004.

Number: January 31,

**OMB APPROVAL** 

imated average

Estimated average burden hours per response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and A Person * Roth Day		eporting	2. Date of Event Requiring Statement (Month/Day/Year)			or Trading Symbol CEUTICALS, INC. [INFI]
(Last)	(First)	(Middle)	01/31/2014	4. Relations Person(s) to	hip of Reporting Issuer	<ol> <li>5. If Amendment, Date Original Filed(Month/Day/Year)</li> </ol>
C/O INFINI PHARMAC INC., 780 DRIVE	CEUTICAI			Directo _X_ Office (give title belo		Owner  ow)  6 Individual or Joint/Group
CAMBRID	GE, MA	02139				Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)	Table I - N	Non-Deriva	ative Securit	ies Beneficially Owned
1.Title of Secu (Instr. 4)	ırity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common St	tock		79		I	By 401(k)
Reminder: Rep	_		each class of securities benefic	ially	SEC 1473 (7-02	2)
	infor	mation con	spond to the collection of tained in this form are not	t		

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security
2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

Expiration Date (Month/Day/Year)

Derivative Security

3. Title and Amount of 4.

Securities Underlying Conversion Ownership or Exercise Form of (Instr. 5)

#### Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 3

			(Instr. 4)		Price of	Derivative	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	09/06/2023	Common Stock	19,248	\$ 20.78	D	Â
Stock Option (Right to Buy)	(1)	09/06/2023	Common Stock	40,752	\$ 20.78	D	Â
Stock Option (Right to Buy)	(2)	01/10/2024	Common Stock	5,333	\$ 12.91	D	Â
Stock Option (Right to Buy)	(2)	01/30/2024	Common Stock	100,000	\$ 13.62	D	Â

### **Reporting Owners**

Reporting Owner Name / Address	Relationships				
- Topotong o mar rumay rumay	Director	10% Owner	Officer	Other	
Roth David C/O INFINITY PHARMACEUTICALS, INC. 780 MEMORIAL DRIVE CAMBRIDGE. MA 02139	Â	Â	Chief Medical Officer	Â	

### **Signatures**

/s/David Roth	02/07/2014
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to 12/48th of the shares on September 6, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.
- (2) The option vests as to 1/48th of the shares on January 31, 2014 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2